288 related articles for article (PubMed ID: 25294906)
21. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
22. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
23. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
24. Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.
Means C; Clayburgh DR; Maloney L; Sauer D; Taylor MH; Shindo ML; Coussens LM; Tsujikawa T
Head Neck; 2019 Aug; 41(8):2636-2646. PubMed ID: 30896061
[TBL] [Abstract][Full Text] [Related]
25. Circulating Myeloid-derived Suppressor Cells Facilitate Invasion of Thyroid Cancer Cells by Repressing miR-486-3p.
Chen L; Xiong L; Hong S; Li J; Huo Z; Li Y; Chen S; Zhang Q; Zhao R; Gingold JA; Zhu X; Lv W; Li Y; Yu S; Xiao H
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32492708
[TBL] [Abstract][Full Text] [Related]
26. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
27. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
28. IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape
Hu JQ; Lei BW; Wen D; Ma B; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Li DS; Ji QH; Liao T
J Cancer; 2020; 11(14):4250-4260. PubMed ID: 32368308
[TBL] [Abstract][Full Text] [Related]
29. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl‑1 pathway.
Qu N; Hu JQ; Liu L; Zhang TT; Sun GH; Shi RL; Ji QH
Int J Oncol; 2017 May; 50(5):1683-1692. PubMed ID: 28393212
[TBL] [Abstract][Full Text] [Related]
30. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.
Ryder M; Gild M; Hohl TM; Pamer E; Knauf J; Ghossein R; Joyce JA; Fagin JA
PLoS One; 2013; 8(1):e54302. PubMed ID: 23372702
[TBL] [Abstract][Full Text] [Related]
31. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
[TBL] [Abstract][Full Text] [Related]
33. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
34. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
[TBL] [Abstract][Full Text] [Related]
35. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
36. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
37. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
38. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
39. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.
Qing W; Fang WY; Ye L; Shen LY; Zhang XF; Fei XC; Chen X; Wang WQ; Li XY; Xiao JC; Ning G
Thyroid; 2012 Sep; 22(9):905-10. PubMed ID: 22870901
[TBL] [Abstract][Full Text] [Related]
40. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.
Lu H; Zhang L; Dai Y; Ruan Y; Cao X; Cai X; Ruan S; Chen Q
Diagn Pathol; 2020 Feb; 15(1):16. PubMed ID: 32050977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
